NCT05725876View on ClinicalTrials.gov

Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 6, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

January 6, 2027

Conditions
PsoriasisCrohn Disease
Interventions
DRUG

Ustekinumab

Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.

Trial Locations (1)

9713GZ

RECRUITING

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER